NovaBridge Biosciences Company Description

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States.

The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer.

The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors.

It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab.

The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025.

NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

NovaBridge Biosciences

Country	Cayman Islands
Founded	2014
Industry	Biological Products, Except Diagnostic Substances
Employees	30
CEO	Xi-Yong Fu

Contact Details

Address: 2440 Research Boulevard Rockville, Maryland 20850 United States
Phone	240 745 6330
Website	novabridge.com

Stock Details

Ticker Symbol	0VY
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Xi-Yong Fu	Chief Executive Officer
Ming Lei	Chief Financial Officer
Tyler Ehler	Head of Investor Relations